Nicox S.A. Logo

Nicox S.A.

ISIN

FR0013018124

Ticker

COX

Sector

Health Care

Sub-Industry

Pharmaceuticals

Country

France

Year Founded

1996

About Nicox S.A.

Company Description

Developing innovative ocular solutions

Nicox is an international ophthalmology company developing innovative therapeutics to help maintain vision and improve ocular health.

We plan to keep the maximum of options open for the company by maintaining rights to our novel therapeutics for eye diseases in key territories, such as the U.S. and Europe, as we create value by advancing their development, maintaining the potential for direct marketing, licensing for certain territories and growth through strategic transactions.

We are focused on the discovery, development and commercialization of novel ophthalmic therapeutics for eye diseases.

Headcount

32

Served Area

Worldwide

Headquarters

Drakkar 2 - Bâtiment D 2405 Route des Dolines
6560, Valbonne
France

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022
Assets N/A 142,266,000.00 114,609,000.00
Noncurrent Assets N/A 89,745,000.00 66,871,000.00
Property Plant And Equipment N/A 1,166,000.00 1,023,000.00
Goodwill N/A 23,663,000.00 25,637,000.00
Intangible Assets Other Than Goodwill N/A 64,848,000.00 39,974,000.00
Other Noncurrent Financial Assets N/A 68,000.00 237,000.00
Current Assets N/A 52,521,000.00 47,738,000.00
Current Trade Receivables N/A 1,723,000.00 1,086,000.00
Current Prepaid Expenses N/A 2,630,000.00 2,853,000.00
Other Current Receivables N/A 736,000.00 1,452,000.00
Cash and cash equivalents 28,102,000.00 47,195,000.00 41,970,000.00
Other Current Assets N/A 237,000.00 377,000.00
Equity And Liabilities N/A 142,266,000.00 114,609,000.00
Equity 109,309,000.00 100,835,000.00 75,552,000.00
Issued Capital N/A 37,030,000.00 43,138,000.00
Retained Earnings N/A -467,144,000.00 -508,892,000.00
Share Premium N/A 528,595,000.00 536,200,000.00
Treasury Shares N/A 605,000.00 847,000.00
Noncurrent Liabilities N/A 26,027,000.00 31,057,000.00
Noncurrent Provisions N/A 730,000.00 661,000.00
Deferred Tax Liabilities N/A 11,868,000.00 9,236,000.00
Current Liabilities N/A 15,404,000.00 8,000,000.00
Trade And Other Current Payables To Trade Suppliers N/A 2,421,000.00 3,649,000.00
Other Current Liabilities N/A 2,163,000.00 2,035,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
Revenue 12,907,000.00 7,233,000.00
Revenue From Contracts With Customers 14,423,000.00 8,583,000.00
Other Income 1,083,000.00 843,000.00
Amortisation Expense 1,252,000.00 1,205,000.00
Profit Loss From Operating Activities -6,760,000.00 -46,010,000.00
Finance Income 1,168,000.00 3,456,000.00
Finance Costs 12,478,000.00 4,851,000.00
Profit Loss Before Tax -18,070,000.00 -47,405,000.00
Income Tax Expense Continuing Operations 28,000.00 -3,644,000.00
Profit (loss) -18,098,000.00 -43,761,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022
Profit (loss) N/A -18,098,000.00 -43,761,000.00
Adjustments For Decrease Increase In Other Operating Receivables N/A 128,000.00 -716,000.00
Adjustments For Depreciation And Amortisation Expense N/A 1,743,000.00 29,421,000.00
Adjustments For Provisions N/A 6,000.00 -67,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A 2,290,000.00 -2,276,000.00
Adjustments For Sharebased Payments N/A 1,314,000.00 1,463,000.00
Adjustments For Losses Gains On Disposal Of Noncurrent Assets N/A 0.00 -8,000.00
Cash Flows From Used In Operating Activities N/A -5,392,000.00 -18,481,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities N/A 20,000.00 8,000.00
Purchase Of Intangible Assets Classified As Investing Activities N/A 0.00 0.00
Cash Flows From Used In Investing Activities N/A 4,949,000.00 -175,000.00
Proceeds From Issuing Shares N/A 13,954,000.00 13,713,000.00
Payments To Acquire Or Redeem Entitys Shares N/A 633,000.00 -91,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 380,000.00 395,000.00
Cash Flows From Used In Financing Activities N/A 19,584,000.00 13,409,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 19,141,000.00 -5,246,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A -48,000.00 21,000.00
Cash and cash equivalents 28,102,000.00 47,195,000.00 41,970,000.00

Please note that some sums might not add up.

Filings & Publications

  • Consolidated Report 2021 - Q4 French 🇫🇷

Capital Markets Information

ISIN

FR0013018124

LEI

969500EZGEO9W4JXR353

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Euronext Paris

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.